{"name":"Kolon TissueGene, Inc.","slug":"kolon-tissuegene-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Sham Control","genericName":"Sham Control","slug":"sham-control","indication":"Other","status":"phase_3"},{"name":"TG-C","genericName":"TG-C","slug":"tg-c","indication":"Articular cartilage defects of the knee","status":"phase_3"},{"name":"TissueGene-C","genericName":"TissueGene-C","slug":"tissuegene-c","indication":"Cirrhosis","status":"phase_3"}]}],"pipeline":[{"name":"Sham Control","genericName":"Sham Control","slug":"sham-control","phase":"phase_3","mechanism":"Sham Control is a placebo comparator used in clinical trials and does not exert any pharmacological effect.","indications":[],"catalyst":""},{"name":"TG-C","genericName":"TG-C","slug":"tg-c","phase":"phase_3","mechanism":"TG-C is a gene therapy that delivers TGF-β3 to cartilage tissue to promote cartilage regeneration and repair.","indications":["Articular cartilage defects of the knee"],"catalyst":""},{"name":"TissueGene-C","genericName":"TissueGene-C","slug":"tissuegene-c","phase":"phase_3","mechanism":"TissueGene-C is a gene therapy that uses a viral vector to deliver the human hepatocyte growth factor (HGF) gene to the liver, promoting tissue repair and regeneration.","indications":["Cirrhosis","Liver failure"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTE1kamc3STMxanJzejl5X0I2d19zbzBpVEIyV1JIUG9Qemc3dzEtZTJudGlzX1hyYTRNc3ZPaGJkZk5leWdTLXlKSDRzSnFCNXRtTjVqVW13RdIBV0FVX3lxTE1kamc3STMxanJzejl5X0I2d19zbzBpVEIyV1JIUG9Qemc3dzEtZTJudGlzX1hyYTRNc3ZPaGJkZk5leWdTLXlKSDRzSnFCNXRtTjVqVW13RQ?oc=5","date":"2026-04-02","type":"pipeline","source":"aju press","summary":"Korean Pharma-Bio Briefing: Kolon Life Science, Daewoong, Celltrion, Daewon, Samsung Medical Center - aju press","headline":"Korean Pharma-Bio Briefing: Kolon Life Science, Daewoong, Celltrion, Daewon, Samsung Medical Center","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-22","type":"pipeline","source":"simplywall.st","summary":"Kolon TissueGene, Inc. (KOSDAQ:950160): When Will It Breakeven? - simplywall.st","headline":"Kolon TissueGene, Inc. (KOSDAQ:950160): When Will It Breakeven?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOTlBYQlVNMlBpMjcwLXU3LVFnZ0hRRTB1ekpOcXVid0FVd0c2NlBQbmdhWDJKNmR6NkdRY1lsLTFoVERvTFpXTXpaVjVIQUc1NEc0THZwMllTWEtPcEpDVDJFdXFVTTRNcmNLeXh4MlpNYzd1M0hMY1gzRVVIM0w4bTQ4X3Q3QTJfYU9MVU1kYlNZV3Zwc1NXRXJ3?oc=5","date":"2026-01-20","type":"trial","source":"Seoul Economic Daily","summary":"Korean Pharma Companies to Unveil Key Clinical Trial Results in 2025 - Seoul Economic Daily","headline":"Korean Pharma Companies to Unveil Key Clinical Trial Results in 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9GTkVEX2hqbUtWSzNJeXU4WUJPb010aWNwNVdibWFNUFZIejRoOW1rMENrcTNYd2RIMmdwdW9HLWI4TUUxV2cycThpaHhJWnByQUF5VmV6NnM5QWtBS0RUd0hudktNNVc0WUN5QnFR0gFyQVVfeXFMTkU0STlWazdITmVrZnJVU1AwN3FBTDJRT05pdnJCSlBGSVhCbFdsaVJzc0RiLTQ3S0Q4cnZaSVlOdW5YeGxudEdFaTdScFFIOEJuMkhwMFlfN21POS1HVWNKOGl4ckRMRThPSmltME5laWdn?oc=5","date":"2026-01-14","type":"trial","source":"koreabiomed.com","summary":"[JPM 2026] Kolon TissueGene courts partners for knee osteoarthritis therapy as phase 3 data near - koreabiomed.com","headline":"[JPM 2026] Kolon TissueGene courts partners for knee osteoarthritis therapy as phase 3 data near","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQa1RlUGFuX2JYWk5WZ3NsUGN4SXhlWXhzVzJkYTgzdEJSQ0dja3JPV3ljOUZpSHhlckxkZ0Jya0dGUE9NcWt4bW1FblVjRGVMZnRIZjNFbTRhcmhsNDhON2RTTUFndkhJOFJpYmFoOXZNWGVtOVJkUDhaTzF0WmlzQdIBlAFBVV95cUxPQ1paZmptdmpyUm92ME1wR3VhV214bDU3QWVFMFdOZFRSd3lBUUppYXJHN1g1RUJVVzFVa2k3Vk5BQ1VHVUUtLU9Oc2MyM0dieHRieS1FcnE3UHRoYms0UVhKU3Nha3NkWHJhT0FGRjA0V1ktdnZROVZFN1hReklVRnBtTTIyWkc1eW93VHdiZ2phWjR3?oc=5","date":"2025-11-28","type":"pipeline","source":"Chosunbiz","summary":"Kolon TissueGene jumps 20% after securities firms raise target price 50% - CHOSUNBIZ - Chosunbiz","headline":"Kolon TissueGene jumps 20% after securities firms raise target price 50% - CHOSUNBIZ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNYTRmOVZXWFBUVVRTaTFjcGlUR0NnUzl3VWVNRjVtQUlJNW1rdWxrNnpqWHdFY2d1V3h0aGgzSVFGbXYzd2ZPQW9ORW44czkxR2MwWXV0VWZOUENGOTRIWlZMOXBaZnptRjJhM09LQ2hudnFLQkQtUjU5ZWtEWDFPUGo5aEdsalVq?oc=5","date":"2025-10-24","type":"pipeline","source":"조선일보","summary":"Kolon Group Appoints Kim Yeong-bom as Kolon Global CEO - 조선일보","headline":"Kolon Group Appoints Kim Yeong-bom as Kolon Global CEO - 조선일보","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE04U1JpNnczN080Z19QNklLNEZ2TjZnVTEtZnNNU1RGZkNNTXp3LVQ4TFo5emlZZVFMQVRFZnE1T09icDFBRlVnSzN6dU5lbzFROWI4?oc=5","date":"2025-10-24","type":"pipeline","source":"매일경제","summary":"Kolon Group appointed Kim Young-beom, CEO of Kolon ENP, as CEO of Kolon Global on the 24th, and cond.. - 매일경제","headline":"Kolon Group appointed Kim Young-beom, CEO of Kolon ENP, as CEO of Kolon Global on the 24th, and cond.. - 매일경제","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxOUlZNcDZjYWxVbTZwRktTWmtnVERhMWFOa2Y1SE4yTVNaUGRwdnN4NDlpdXB3WExWcWhBU1h4ZlRjMUY0UE9NdEJsZUQtUzVzWUV0M29pcTZlb3VLTXdlWi1HQ055b3Rvei1GQmVHS1dXTjJ3a2t4YTNYWl9QcFFWUXB6Ny1BMVAyX2ZXWER3UUtKX3p1akh4bmFhY1R4UEs2UUpNN09SMmhnWjNwRTRleVNfUEdMdUFESW9UbkRGLXBOeURuZm1WQzRlRnNhb2NtRFJXbjkyMlZSSkpTTmt6blQ1X3JxNGRiaGsyVjNvYw?oc=5","date":"2025-04-21","type":"pipeline","source":"CRISPR Medicine News","summary":"Press Release Service: Advanced Therapy Medicinal Products Global Strategic Business Report 2025, with Profiles of Bluebird Bio, Gilead Sciences, JCR Pharmaceuticals, Kolon TissueGene, MediPost, Organ","headline":"Press Release Service: Advanced Therapy Medicinal Products Global Strategic Business Report 2025, with Profiles of Blueb","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFA4aDBOVjVjdUZ0ei1RY2F5ZUpTemEteHh0d2RkRTZZVWkwb1lXTm1CbE9RSzI3anh0LW00QVBIVElENkNVTWNHbkdaRDI5amJUang1RkxMRWVMNkViTmZwZi1laUJETWNzWHh3OTR30gFyQVVfeXFMTlY3aHU5TEdpaC0zSlB6VHhyOG11ZVNtcUJyczdKSjdUWExGNldvcjB5enFlUmRMVGdxVGxXSWtaazU0Z25UVFFtaUx6NFlIRnhMSTZQX3p6MkxlcEt1WkloZzJBVzRCcVRIM2JWTDZfeEZR?oc=5","date":"2022-10-24","type":"pipeline","source":"koreabiomed.com","summary":"Kolon TissueGene shares to resume trading on Kosdaq from Oct.25 - koreabiomed.com","headline":"Kolon TissueGene shares to resume trading on Kosdaq from Oct.25","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5aVnFFckVGZXFRNldBZ1JTRWZKYUhNWFQxcWdlaGRUeEw1X1Q2WlZIbFpVc0dGTXE1VXFjVTZXUXV6VlVoWnZuTVR4VkdES2dsSkJtNHRSRjlkSlh5TTVTbWxucnJoY1BnY2o4Zmln?oc=5","date":"2022-04-13","type":"deal","source":"KED Global","summary":"Kolon Life inks technology transfer deal with Juniper Biologics - KED Global","headline":"Kolon Life inks technology transfer deal with Juniper Biologics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE5LOE5yZndOOWp6WDJqc2RKNTNHN1YyckF0WHlDS3RqaTI2U0V5dUY4bkswaHZudW5pNjhkZ0k5YVZUM2h5aW9NblB0Ujc3VmgtbWNNTFNuQWFPN3ZhWnBVYTNSclhvWm1KcXdlNVpuOUJoV0Q0?oc=5","date":"2021-12-28","type":"trial","source":"KED Global","summary":"Kolon resumes Invossa phase 3 clinical trials in US - KED Global","headline":"Kolon resumes Invossa phase 3 clinical trials in US","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxNU1FfUHJKZVV2NTdvX3J6LTRsWFJVcUFoeWFLSzRrRmR0R2pfZXVIcU1RMWs4SUx0TGFxXy1KM0pSV0NJOUwxMFRLV0R1d1pkRzVxbjhfbEw5dWoyMEh4RWl1VWtTdFplSUVFRGNOZEx0aVpEMVljNHI1MTVYSG5SNkxRZHhKOHcxVFlxT09sNGxFZFhsOUlDZDk1TjVjYngyQVRZaENNYw?oc=5","date":"2019-05-07","type":"pipeline","source":"Korea JoongAng Daily","summary":"Invossa scandal continues to build - Korea JoongAng Daily","headline":"Invossa scandal continues to build","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":3},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}